The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010Patient-specific iPS cell-derived Neurons and Disease-associated LRRK2 Mutations for Parkinson's Disease Research
Objective/Rationale:
Several underlying genetic risk factors are now established for Parkinson’s disease (PD). Mutations in LRRK2 are the most common genetic cause of the selective neurodegeneration... -
Therapeutics Development Initiative, 2010Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease
Objective/Rationale:
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and... -
MJFF Research Grant, 2010Validation of Enzymatic Activity and Neuropathology in G2019S LRRK2-induced Dopaminergic Neurodegeneration in a Pre-clinical Model of Parkinson's Disease
Objective/Rationale:
Mutations in the LRRK2 gene are a common cause of familial and sporadic Parkinson’s disease. Familial LRRK2 mutations induce neuronal toxicity in vitro. Reliable pre-clinical... -
MJFF Research Grant, 2010Generation and Characterization of iPS Neurons from PINK1- and Parkin-linked Parkinson's Disease
Objective/Rationale:
Recent reports have demonstrated that skin cells from patients with Parkinson’s disease can be reprogrammed into pluripotent stem cells (iPS) and subsequently differentiated into... -
MJFF Research Grant, 2010Generation and Characterization of iPS Neurons from PINK1- and Parkin-linked Parkinson's Disease
Objective/Rationale:
Recent reports have demonstrated that skin cells from patients with Parkinson’s disease can be reprogrammed into pluripotent stem cells (iPS) and subsequently differentiated into... -
MJFF Research Grant, 2010Support for your Collaboration on Proof-of-concept clinical trial on the use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-induced Dyskinesias. - Linked to Bjorklund CIA 2009
Objective/Rationale:
We have identified a new potential drug target for Parkinson's disease -- receptors located on the so-called serotonin neurons in the brain -- for alleviation of involuntary...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.